{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T02:03:14Z","timestamp":1781661794905,"version":"3.54.5"},"reference-count":54,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"J. Allyn Taylor & Arthur H. Mingay Chair in Management Science"},{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["MDM Policy &amp; Practice"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:p> Background. Pharmaceutical risk sharing agreements (RSAs) are commonly used to manage uncertainties in costs and\/or clinical benefits when new drugs are added to a formulary. However, existing mathematical models of RSAs ignore the impact of RSAs on clinical and financial risk. Methods. We develop a model in which the number of patients, total drug consumption per patient, and incremental health benefits per patient are uncertain at the time of the introduction of a new drug. We use the model to evaluate the impact of six common RSAs on total drug costs and total net monetary benefit (NMB). Results. We show that, relative to not having an RSA in place, each RSA reduces expected total drug costs and increases expected total NMB. Each RSA also improves two measures of risk by reducing the probability that total drug costs exceed any threshold and reducing the probability of obtaining negative NMB. However, the effects on variance in both NMB and total drug costs are mixed. In some cases, relative to not having an RSA in place, implementing an RSA can increase variability in total drug costs or total NMB. We also show that, for some RSAs, when their parameters are adjusted so that they have the same impact on expected total drug cost, they can be rank-ordered in terms of their impact on variance in drug costs. Conclusions. Although all RSAs reduce expected total drug costs and increase expected total NMB, some RSAs may actually have the undesirable effect of increasing risk. Payers and formulary managers should be aware of these mean-variance tradeoffs and the potentially unintended results of RSAs when designing and negotiating RSAs. <\/jats:p>","DOI":"10.1177\/2381468321990404","type":"journal-article","created":{"date-parts":[[2021,2,13]],"date-time":"2021-02-13T10:21:45Z","timestamp":1613211705000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["How Risky Is That Risk Sharing Agreement? Mean-Variance Tradeoffs and Unintended Consequences of Six Common Risk Sharing Agreements"],"prefix":"10.1177","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6924-9013","authenticated-orcid":false,"given":"Gregory S.","family":"Zaric","sequence":"first","affiliation":[{"name":"Ivey Business School, Western University, and Department of Epidemiology and Biostatistics, Schulich School of Medicine and Dentistry, Western University, London, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,2,9]]},"reference":[{"key":"bibr1-2381468321990404","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-019-00838-w"},{"key":"bibr2-2381468321990404","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-014-0093-x"},{"key":"bibr3-2381468321990404","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-017-0559-4"},{"key":"bibr4-2381468321990404","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-10-153"},{"key":"bibr5-2381468321990404","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2019.1601060"},{"key":"bibr6-2381468321990404","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462317001106"},{"key":"bibr7-2381468321990404","unstructured":"National Institute for Health and Care Excellence. Patient access schemes liaison unit [cited July 26, 2016]. Available from: https:\/\/www.nice.org.uk\/about\/what-we-do\/patient-access-schemes-liaison-unit\/list-of-technologies-with-approved-patient-access-schemes"},{"key":"bibr8-2381468321990404","doi-asserted-by":"publisher","DOI":"10.1016\/j.healthpol.2016.07.017"},{"key":"bibr9-2381468321990404","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-016-0420-1"},{"key":"bibr10-2381468321990404","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2014.09.007"},{"key":"bibr11-2381468321990404","volume":"2","author":"Williamson S","year":"2010","journal-title":"Clin Pharm"},{"key":"bibr12-2381468321990404","doi-asserted-by":"publisher","DOI":"10.3310\/hta20810"},{"key":"bibr13-2381468321990404","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2016.1215991"},{"key":"bibr14-2381468321990404","doi-asserted-by":"publisher","DOI":"10.1002\/hec.4112"},{"key":"bibr15-2381468321990404","doi-asserted-by":"publisher","DOI":"10.1186\/s13561-019-0242-x"},{"issue":"10","key":"bibr16-2381468321990404","volume":"23","author":"Nazareth T","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"bibr17-2381468321990404","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2014.11.003"},{"key":"bibr18-2381468321990404","doi-asserted-by":"publisher","DOI":"10.1017\/S1744133111000016"},{"key":"bibr19-2381468321990404","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0614-8"},{"key":"bibr20-2381468321990404","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2016.1176576"},{"key":"bibr21-2381468321990404","doi-asserted-by":"publisher","DOI":"10.1057\/jors.2013.106"},{"key":"bibr22-2381468321990404","doi-asserted-by":"publisher","DOI":"10.1002\/hec.976"},{"key":"bibr23-2381468321990404","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-013-0544-6"},{"key":"bibr24-2381468321990404","doi-asserted-by":"publisher","DOI":"10.1002\/hec.1603"},{"key":"bibr25-2381468321990404","doi-asserted-by":"publisher","DOI":"10.1002\/hec.3522"},{"key":"bibr26-2381468321990404","doi-asserted-by":"publisher","DOI":"10.1287\/mnsc.2019.3574"},{"key":"bibr27-2381468321990404","doi-asserted-by":"crossref","unstructured":"Olsder W, Martagan T, Tang CS. Improving Access to Rare Disease Treatments: Subsidy, Pricing, and Payment Schemes. SSRN; 2019. Available from: https:\/\/papers.ssrn.com\/sol3\/papers.cfm?abstract_id=3481150","DOI":"10.2139\/ssrn.3481150"},{"key":"bibr28-2381468321990404","doi-asserted-by":"publisher","DOI":"10.1111\/j.1937-5956.2011.01219.x"},{"issue":"3","key":"bibr29-2381468321990404","volume":"18","author":"Levaggi R","year":"2020","journal-title":"Appl Health Econ Health Policy"},{"key":"bibr30-2381468321990404","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2009.00510.x"},{"key":"bibr31-2381468321990404","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2013.11.048"},{"key":"bibr32-2381468321990404","doi-asserted-by":"publisher","DOI":"10.1002\/hec.3903"},{"issue":"1","key":"bibr33-2381468321990404","first-page":"77","volume":"7","author":"Markowitz H","year":"1952","journal-title":"J Finance"},{"key":"bibr34-2381468321990404","doi-asserted-by":"publisher","DOI":"10.1017\/S0269964804184039"},{"key":"bibr35-2381468321990404","volume-title":"Actuarial Mathematics","author":"Bowers NL","year":"1986"},{"key":"bibr36-2381468321990404","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462300011442"},{"issue":"5","key":"bibr37-2381468321990404","volume-title":"Health Policy","volume":"122","author":"Dunlop WCN","year":"2018"},{"key":"bibr38-2381468321990404","doi-asserted-by":"publisher","DOI":"10.1016\/j.healthpol.2018.01.006"},{"key":"bibr39-2381468321990404","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-8-198"},{"key":"bibr40-2381468321990404","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39238.353657.DB"},{"key":"bibr41-2381468321990404","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70380-2"},{"key":"bibr42-2381468321990404","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.191292"},{"key":"bibr43-2381468321990404","unstructured":"Canadian Cancer Society. Multiple myeloma statistics [cited August 19, 2020]. Available from: https:\/\/www.cancer.ca\/en\/cancer-information\/cancer-type\/multiple-myeloma\/statistics\/?region=on"},{"key":"bibr44-2381468321990404","unstructured":"Myeloma Canada. Canadian statistics for multiple myeloma [cited August 19, 2020]. Available from: https:\/\/www.myelomacanada.ca\/en\/about-multiple-myeloma\/what-is-myeloma\/statistics."},{"issue":"4","key":"bibr45-2381468321990404","volume":"8","author":"Roy A","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"bibr46-2381468321990404","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.04.014"},{"key":"bibr47-2381468321990404","volume":"2","author":"Thorp H","year":"2010","journal-title":"Clin Pharm"},{"key":"bibr48-2381468321990404","unstructured":"Department of Health. Hints and tips for companies considering a Patient Access Scheme (PAS) proposal in England [cited January 12, 2021]. Available from: https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/217037\/PAS-Good-Practice-Guidance.pdf"},{"key":"bibr49-2381468321990404","unstructured":"Caffrey M. Aetna, Merck reach value-based deal on diabetes drugs and collaborate on wellness [cited July 14, 2020]. Available from: https:\/\/www.ajmc.com\/focus-of-the-week\/aetna-merck-reach-value-based-reimbursement-deal-on-diabetes-drugs-to-collaborate-on-wellness-initiative"},{"key":"bibr50-2381468321990404","doi-asserted-by":"publisher","DOI":"10.1002\/mde.1342"},{"key":"bibr51-2381468321990404","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-020-00601-9"},{"key":"bibr52-2381468321990404","doi-asserted-by":"publisher","DOI":"10.1002\/hec.897"},{"key":"bibr53-2381468321990404","unstructured":"Pan-Canadian Oncology Drug Review. pCODR Expert Review Committee (pERC): initial recommendation [cited January 12, 2021]. Available from: https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/pcodr-pomalyst-mm-in-rec.pdf"},{"key":"bibr54-2381468321990404","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2015.1096021"}],"container-title":["MDM Policy &amp; Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2381468321990404","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2381468321990404","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2381468321990404","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T18:10:55Z","timestamp":1740939055000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2381468321990404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.1177\/2381468321990404"],"URL":"https:\/\/doi.org\/10.1177\/2381468321990404","relation":{},"ISSN":["2381-4683","2381-4683"],"issn-type":[{"value":"2381-4683","type":"print"},{"value":"2381-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]},"article-number":"2381468321990404"}}